Global Third Generation Ventricular Assist Devices Market– Industry Trends and Forecast to 2030

 Third Generation Ventricular Assist Devices Market Analysis and Size

According to the World Health Organization 2021, an estimated 17.9 million people die each year as a result of cardiovascular diseases worldwide. This accounts for 35% of all deaths worldwide. Furthermore, heart attacks and stroke account for 85% of all cardiovascular disease deaths. According to a July 2020 article published in Cureus Journal of Medical Science, ischemic heart disease (IHD) is a leading cause of death worldwide. Ischemic heart disease affects approximately 126 million people (1,655 per 100,000), or about 1.72% of the world's population. By 2030, the global prevalence of ischemic heart disease is expected to exceed 1,845 per 100,000 people.

Data Bridge Market Research analyses that the third generation ventricular assist devices market which was USD 2.5 billion in 2022, is expected to reach USD 9.08 billion by 2030, at a CAGR of 17.50% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Third Generation Ventricular Assist Devices Market Scope and Segmentation      

Definición de mercado

Los dispositivos de asistencia ventricular (VAD) de tercera generación son bombas rotativas de flujo continuo con un impulsor/rotor totalmente levitado y sin contacto mecánico entre las partes rotatorias y estacionarias de la bomba en funcionamiento normal. Los VAD de tercera generación han surgido con la promesa de una hemocompatibilidad y durabilidad mejoradas en comparación con los dispositivos de segunda generación. Sin embargo, la mayoría de los dispositivos de tercera generación no han demostrado una ventaja significativa sobre sus contrapartes de segunda generación, y con frecuencia intercambian una mejora en un aspecto del rendimiento por una desventaja en otro.

Dinámica del mercado mundial de dispositivos de asistencia ventricular de tercera generación

Conductores

• Avances tecnológicos

El mercado de los dispositivos de asistencia vascular está en constante cambio y los actores clave invierten en innovación y desarrollo de productos. Se espera que el mercado de los dispositivos de asistencia vascular esté impulsado por avances tecnológicos combinados con aprobaciones regulatorias oportunas en forma de dispositivos de tamaño pequeño con características como el control de infecciones. Berlin Heart anunció en junio de 2020 que se completó la aprobación posterior a la comercialización (PMA) requerida por la FDA de EE. UU. para el dispositivo de asistencia vascular pediátrico EXCOR. Además, los beneficios asociados con el uso de los dispositivos de asistencia vascular incluyen una mayor conformidad, funcionalidad y durabilidad, que aumentan la adopción del producto y, por lo tanto, respaldan el crecimiento del mercado.

• Empresas de capital privado en ascenso

Las empresas de capital privado y los inversores de riesgo están realizando inversiones en el creciente mercado de VAD de tercera generación para promover el desarrollo de productos. Por ejemplo, CorWave recaudó 40,0 millones de dólares en una ronda de financiación de serie C liderada por tres inversores nuevos y antiguos en enero de 2021 para su bomba cardíaca implantable basada en una tecnología novedosa, la bomba de membrana de onda, entre ellos Novo Holdings, Bpifrance, Sofinnova Partners, Seventure, Ysios Capital, la Comisión Europea, la oficina familiar de Singapur M&L Healthcare y Financière Arbevel.

Oportunidades

• Nuevos avances

Se espera que los avances en nuevos dispositivos de asistencia ventricular (VAD) para intervenciones quirúrgicas, en particular en pacientes pediátricos que padecen trastornos cardíacos, aumenten la demanda. Por ejemplo, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) clasificó los dispositivos de asistencia ventricular izquierda (LVAD) de flujo continuo, Micromed HeartAssist 5TM Pediatric VAD y Berlin HeartTM EXCOR pediátrico para pacientes pediátricos. Desde 2011, Berlin HeartTM EXCOR ha sido aprobado para su uso como dispositivo puente para el trasplante.

• Aumento de la incidencia del trasplante de órganos.

La creciente prevalencia de enfermedades cardiovasculares y los crecientes riesgos de insuficiencia orgánica están impulsando el crecimiento de la demanda de trasplantes de órganos. La escasez de donantes de órganos retrasa el procedimiento de trasplante de órganos. Según United Network for Organ Sharing, casi 121.016 personas necesitan un trasplante de órganos y aproximadamente 77.725 personas están en la lista de espera activa.

Restricciones/Desafíos

• Costos elevados

Los altos costos asociados con el procedimiento y el uso del dispositivo, la falta de políticas de reembolso gubernamentales y un número cada vez mayor de riesgos graves involucrados en el procedimiento están actuando como restricciones del mercado para el crecimiento de los dispositivos de asistencia ventricular de tercera generación durante el período de pronóstico. El desafío más difícil para el crecimiento del mercado será el mayor desarrollo de dispositivos asequibles, pequeños y eficientes.

Este informe de mercado de dispositivos de asistencia ventricular de tercera generación proporciona detalles de nuevos desarrollos recientes, regulaciones comerciales, análisis de importación y exportación, análisis de producción, optimización de la cadena de valor, participación de mercado, impacto de los actores del mercado nacional y localizado, analiza oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, análisis estratégico del crecimiento del mercado, tamaño del mercado, crecimientos del mercado de categorías, nichos de aplicación y dominio, aprobaciones de productos, lanzamientos de productos, expansiones geográficas, innovaciones tecnológicas en el mercado. Para obtener más información sobre el mercado de dispositivos de asistencia ventricular de tercera generación, comuníquese con Data Bridge Market Research para obtener un informe de analista, nuestro equipo lo ayudará a tomar una decisión de mercado informada para lograr el crecimiento del mercado.

Impacto de la COVID-19 en el mercado de dispositivos de asistencia ventricular de tercera generación

The ongoing Covid-19 pandemic has had a negative impact on the third generation ventricular assist devices market, with the government imposing temporary lockdowns and travel restrictions, resulting in a decrease in the number of surgical procedures. For instance, the global revenue of the ABIOMED Impella heart pump was impacted in the fourth quarter of FY2020 due to lower patient utilization and the significant impact of the COVID-19 pandemic on surgeries, elective medical procedures, and fewer patients seeking treatment at hospitals.

Recent Developments

• In June 2020, The FDA approved the company's First-in-Human Trial of Impella ECP, which will be studied in high-risk percutaneous coronary intervention patients. In addition, to strengthen their business and expand the reach of their device, they are implementing various strategies such as mergers and acquisitions and expanding their manufacturing facilities.

Global Third Generation Ventricular Assist Devices Market Scope

The third generation ventricular assist devices market is segmented on the basis of product, application, age, flow, design, and technology. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Left Ventricular Assist Devices (LVADs)
• Right Ventricular Assist Devices (RVADs)
• Biventricular Assist Devices (BIVADs)
• Percutaneous Ventricular Assist Devices (PVADs)
• Total Artificial Heart (TAH)

 Application

• Destination Therapy
• Bridge-to-Candidacy (BTC) Therapy
• Bridge-to-Transplant (BTT) Therapy
• Bridge-to-Recovery (BTR) Therapy
• Others

 Age

• Below 18 Years
• 19-39 Years
• 40-59 Years
• 60-79 Years
• Above 80 Years

 Flow

• Pulsatile Flow
• Continuous Flow
• Axial continuous flow
• Centrifugal continuous flow

 Design

• Transcutaneous
• Implantable

 Technology

• Magnetic
• Hydrodynamic Levitation

Third Generation Ventricular Assist Devices Market Regional Analysis/Insights

The third generation ventricular assist devices market is analyzed and market size insights and trends are provided by country, product, application, age, flow, design, and technology as referenced above.

The countries covered in the third generation ventricular assist devices market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the third generation ventricular assist devices market because of rising public health awareness, the prevalence of well-established healthcare policies, and the region's high prevalence of cardiovascular disorders.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the growing number of initiatives such as “Make in India” along with surging levels of investment for the growth of the healthcare sector in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The third generation ventricular assist devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for third generation ventricular assist devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the third generation ventricular assist devices market. The data is available for historic period 2011-20201.

Competitive Landscape and Third Generation Ventricular Assist Devices Market Share Analysis

The third generation ventricular assist devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to third generation ventricular assist devices market.

Some of the major players operating in the third generation ventricular assist devices market are:

• ABIOMED (U.S.)
• Asahi Kasei Corporation (Japan)
• Abbott (U.S.)
• Calon Cardio (U.K.)
• Jarvik Heart, Inc. (U.S.)
• Medtronic (Ireland)
• Terumo Corporation (Japan)
• BiVACOR Inc. (U.S.)
• Cardiobridge GmbH (Germany)
• CHF Solutions, Inc. (U.S.)
• Evaheart, Inc. (U.S.)
• LivaNova PLC (U.K.)
• CorWave SA (France)
• Fresenius Medical Care AG & Co. KGaA (Germany)
• MiTiHeart Corporation (U.S.)
• Getinge AB (Sweden)
• SynCardia Systems, LLC (U.S.)
• Teleflex Incorporated (U.S.)
• Mayo Foundation for Medical Education and Research (MFMER) (U.S.)

Research Methodology: Global Third Generation Ventricular Assist Devices Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report. 

SKU-56781